IP Verse

Dose And Regimen For Hdm2-P53 Interaction Inhibitors

Patent No. EP3541387 (titled "Dose And Regimen For Hdm2-P53 Interaction Inhibitors") was filed by Novartis on Nov 14, 2017. The application was issued on Apr 21, 2021.

Patent Summary

Patent Family

Patent Family

Patent Oppositions (2)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
STRAWMANJan 20, 2022VOSSIUS & PARTNER PATENTANWALTE RECHTSANWALTE MBB
BOEHRINGER INGELHEIMJan 20, 2022D YOUNG

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents

EP3541387

NOVARTIS
Application Number
EP17804304A
Filing Date
Nov 14, 2017
Status
Revoked
Jul 18, 2025
Publication Date
Apr 21, 2021
External Links
Slate, Register , Google Patents